Japanese Journal of Infectious Diseases
Online ISSN : 1884-2836
Print ISSN : 1344-6304
ISSN-L : 1344-6304

This article has now been updated. Please use the final version.

version2
Comparison of clinical and laboratory features and treatment options of 237 symptomatic and asymptomatic children infected with SARS-CoV-2 in the early phase of the COVID-19 pandemic in Turkey
Ahmet Soysal, Erdem Gönüllü, Hüseyin Arslan, Büşra Sultan Kibar, Serdar Pop, Gözde Nur Yurttaş, Hacer Demirbacak, Füsun Ünal, Sedat Öktem, Serkan Atıcı, Arife Derda Yücel Şen, Nalan Karabayır, Metin Karaböcüoğlu, PEDCOVID19 study group.
Author information
Keywords: Hydroxychloroquine, SARS-CoV-2, Turkey
JOURNAL FREE ACCESS Advance online publication

Article ID: JJID.2020.781

The final version of this article is now available: Vol. 74 (2021), No. 4 pp. 273-279
version2： December 01, 2020
version1： November 30, 2020
Details
Download PDF (1114K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract

Since the first report of COVID-19 in December 2019, little is known about therapeutic usage of hydroxychloroquine in pediatric patients with COVID-19. We retrospectively retrieved data for SARS-CoV-2 PCR positive pediatric patients from 20 hospitals in 8 different cities in Turkey. We obtained patients’ epidemiological, clinical, laboratory features and drugs used for treatment of COVID-19. 237 nasopharyngeal swab SARS-CoV-2 PCR positive children were included into the study from March 26 to June 20, 2020. The mean age of asymptomatic children (118±62 months) was found to be higher than that of symptomatic children (89±69 months). Symptomatic children had a significantly lower mean lymphocyte count and higher mean CRP, D-dimer value, procalcitonin and LDH than asymptomatic children in univariate analysis. Out of 156 children, 78 (50%) children received Hydroxychloroquine-containing regimen, 15 of them were treated with hydroxychloroquine + azithromycin + oseltamivir, 44 were treated with hydroxychloroquine + azithromycin and 21 were only treated with hydroxychloroquine. Among the 156 patients who received medical treatment, 90 (58%) patients had pre and/or post-treatment ECG performed upon them. However, none of them either reported ECG abnormalities or a need for discontinuation of hydroxychloroquine because of adverse drug reaction.

Content from these authors
© 2020 Authors
Favorites & Alerts

Recently viewed articles
Predecessor

Japanese Journal of Medical Science and Biology

The Japanese Medical Journal

Share this page
feedback
 Top